文献速递心律失常血脂与心血管预防

低危房颤患者口服抗凝可减少痴呆与卒中

Less dementia and stroke in low-risk patients with atrial fibrillation taking oral anticoagulation.
PubMed 文献 · Eur Heart J · 2019-01-01

倾向评分匹配显示口服抗凝与痴呆风险降低相关(sHR 0.62,95%CI 0.48-0.81),复合脑保护终点风险降低12%(sHR 0.88,95%CI 0.72-1.00),获益主要见于65岁以上患者。

要点

  • 低危房颤患者口服抗凝与痴呆风险降低相关(sHR 0.62)。
  • 复合脑保护终点风险降低12%(sHR 0.88)。
  • 65岁以上患者口服抗凝获益,60岁以下无危险因素者可能弊大于利。

核心结论

  • 低危房颤患者使用口服抗凝药者痴呆风险低于未使用者。
  • 65岁以上患者不论卒中风险评分如何均可能从口服抗凝治疗中获益。

研究设计与样本

  • 采用倾向评分匹配与伪造终点分析,并以死亡作为竞争风险校正。

主要发现

  • 口服抗凝与痴呆风险降低相关(sHR 0.62,95%CI 0.48-0.81)。
  • 口服抗凝与复合脑保护终点风险降低12%相关(sHR 0.88,95%CI 0.72-1.00)。
  • 获益主要限于65岁以上患者,60岁以下无危险因素者口服抗凝可能弊大于利。

临床怎么用

  • 对65岁以上低危房颤患者,评估口服抗凝时应综合考虑痴呆与颅内出血风险,而非仅依据卒中风险评分。
  • 对60岁以下无危险因素的低危患者,启动口服抗凝需谨慎权衡获益与风险。

局限性

  • 回顾性观察性研究,存在残余混杂可能。
  • 结论基于瑞典登记库人群,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To investigate if patients with atrial fibrillation (AF) without clear indication for oral anticoagulant (OAC) due to perceived low stroke risk may benefit from OAC treatment when also dementia and intracerebral bleeding risks are considered. METHODS AND RESULTS: Retrospective study of cross-matched national registries of all individuals in Sweden with a hospital diagnosis of AF between 2006 and 2014 (n = 456 960). Exclusion was made of patients with a baseline CHA2DS2-VASc score >1, not counting female sex, and of patients with previous diagnosis of dementia or intracranial bleeding. After exclusions, 91 254 patients remained in the study of whom 43% used OAC at baseline. Propensity score matching and falsification endpoints were used. Treatment with OAC was associated with lower risk of dementia after adjustment for death as a competing risk [subhazard ratio (sHR) 0.62 with 95% confidence interval (CI) 0.48-0.81]. Regarding the composite brain protection endpoint, OAC treatment was associated with an overall 12% lower risk (sHR 0.88, CI 0.72-1.00). This apparent benefit was restricted to patients aged >65 years, whereas OAC treatment of patients <60 years of age without risk factors appeared to do more harm than good. CONCLUSION: Low-risk AF patients who take OAC have lower risk of dementia than those who do not use OAC. Patients age >65 years appear to benefit from OAC treatment irrespective of stroke risk score.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Friberg L, Andersson T, Rosenqvist M, et al. Less dementia and stroke in low-risk patients with atrial fibrillation taking oral anticoagulation. Eur Heart J. 2019. PMID: 31095295. doi:10.1093/eurheartj/ehz304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。